The therapeutic effects of fenofibrate on blood serum lipid in type ii diabet-ic patients in El-Beida, Libya

The risks of dyslipidemia and cardiovascular diseases are well known to be in- creased in diabetic patients. Moreover, the therapeutic response of fenofibrate drug on blood serum lipid is also known. However, previous studies did not compare the outcomes of feno- fibrate on blood serum levels in patients with type II diabetes mellitus with non-diabetic pa- tients. The purpose of this study was to analyze the outcomes of fenofibrate on blood serum lipid profiles in hyperlipidemic patients with type II diabetes mellitus compared to hyper- lipidemic patients without diabetes mellitus. This study was conducted on 40 type II diabetic patients and 30 non-diabetic patients. Their ages varied 30-55 years and all of them were hy- perlipidemic. Blood serum lipid levels were measured before and once treatment at 1, 2, and 4 months. It was found that the levels of S. Total sterol and S. LDL-C were less in diabetic pa- tients than in non-diabetic patients once they were exploited the different doses of fenofibrate, whereas the changes in S. HDL-C and S. triglyceride were nearly similar in each. Further- more, it was noticed that just about the same responses of S. Total sterol and S. LDL-C reduc- tion were achieved in diabetic patients once they were using a higher dose than that used for non-diabetic patients. Thus, higher doses of fenofibrate are required to reduce blood serum li- pid levels in diabetic patients as compared to non-diabetic patients.